Study Evaluating TTI-237 in Advanced Malignant Solid Tumors

A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00195247

Enrollment

Registered

2005-09-19

Start date

2005-05-31

Completion date

Unknown

Last updated

2007-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Keywords

Tumors, Advanced malignant solid tumors

Brief summary

The purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.

Interventions

DRUGTTI-237

Study design

Allocation

NON_RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Documented diagnosis of malignant solid tumor with measurable disease * Life expectancy of at least 12 weeks * ECOG performance status of 0, 1, or 2

Exclusion criteria

* Recent major surgery, radiation therapy or anti-cancer treatment * History of any other prior malignancy within the last 5 years

Design outcomes

Primary

Measure	Time frame
Primary purpose is to address the safety and tolerability of TTI-237. Patient will be assessed on an ongoing basis during their participation on the trial.	—

Secondary

Measure	Time frame
Preliminary pharmacokinetics (cycle 1 only) and anti-tumor activity of TTI-237 (approximately every 8 weeks).	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026